Novel methods for inducing an immune response

Abstract

The present invention relates to methods for inducing an immune response, in particular methods for inducing an immune response against mycobacterial infections or disease comprising (i) at least one administration of a polypeptide Rv1196 related antigen and at least one administration of an adenovirus encoding a Rv1196 related antigen or (ii) at least one administration of a polypeptide Rv0125 related antigen and at least one administration of an adenovirus encoding a Rv0125 related antigen. Associated compositions, adenoviral constructs and polynucleotide sequences are also provided.

1 - 90 . (canceled) 
     
     
         91 . A method for inducing an immune response in a subject comprising:
 (i) administration of a polypeptide Rv0125 related antigen to the subject, followed by administration of a non-human simian adenovirus encoding a Rv0125 related antigen; or   (ii) administration of a non-human simian adenovirus encoding a Rv0125 related antigen, followed by administration of a polypeptide Rv0125 related antigen to the subject.   
     
     
         92 . The method of  claim 91  wherein the polypeptide Rv0125 related antigen comprises a sequence having at least 90% identity to SEQ ID No: 3. 
     
     
         93 . The method of  claim 91  wherein the polypeptide Rv0125 related antigen comprises a fragment of SEQ ID No: 3 which is at least 150 amino acids in length. 
     
     
         94 . The method of  claim 91  wherein the encoded Rv0125 related antigen comprises a sequence having at least 90% identity to SEQ ID No: 3. 
     
     
         95 . The method of  claim 91  wherein the encoded Rv0125 related antigen comprises a fragment of SEQ ID No: 3 which is at least 150 amino acids in length. 
     
     
         96 . The method of  claim 91 , wherein the polypeptide Rv0125 related antigen is provided in a composition further comprising an adjuvant. 
     
     
         97 . The method of  claim 96 , wherein the adjuvant comprises a Toll Like Receptor (TLR) agonist and/or an immunologically active saponin. 
     
     
         98 . The method of  claim 96  wherein the adjuvant comprises 3-O-deacylated monophosphoryl lipid A (3D-MPL). 
     
     
         99 . The method of  claim 96  wherein the adjuvant comprises QS21. 
     
     
         100 . The method of  claim 91  wherein the non-human simian adenovirus is a chimpanzee adenovirus. 
     
     
         101 . The method of  claim 100  wherein the chimpanzee adenovirus is a ChAd3. 
     
     
         102 . The method of  claim 100  wherein the chimpanzee adenovirus is a ChAd63. 
     
     
         103 . The method of  claim 91 , wherein the Rv0125 related antigen comprises a sequence having at least 90% identity to SEQ ID NO: 6. 
     
     
         104 . The method of  claim 91 , wherein a composition comprising the polypeptide Rv0125 related antigen is substantially free of a non-human simian adenovirus encoding the Rv0125 related antigen. 
     
     
         105 . The method of  claim 91 , wherein a composition comprising the polypeptide Rv0125 related antigen does not include a non-human simian adenovirus encoding the Rv0125 related antigen.